Pharmacology and pharmacokinetics of sedatives and analgesics

Gastrointestinal Endoscopy Clinics of North America

Volumn 14, Issue 2, 2004, Pages 247-268

  Horn, Ed ^a   Nesbit, Suzanne Amato ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALFENTANIL; ANALGESIC AGENT; ANTIFUNGAL AGENT; BENZODIAZEPINE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; CREMEPHOR; DIAZEPAM; DILTIAZEM; FENTANYL; FLUMAZENIL; HYDROMORPHONE; LORAZEPAM; MIDAZOLAM; MORPHINE; NALOXONE; OPIATE; OXAZEPAM; OXYCODONE; PETHIDINE; PHENOL DERIVATIVE; PHENYTOIN; PROPOFOL; PROPYLENE GLYCOL; PYRROLE; REMIFENTANIL; RIFAMPICIN; SEDATIVE AGENT; SUFENTANIL; TEMAZEPAM; UNINDEXED DRUG;

ALLERGY; ANALGESIA; BILE DUCT PRESSURE; CONSTIPATION; DELIRIUM; DIZZINESS; FLUSHING; HUMAN; HYPOTENSION; MENTAL DISEASE; MIOSIS; MYOCLONUS; NAUSEA; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SWEATING; TREMOR; URINE RETENTION; VASODILATATION; VOMITING;

ANALGESICS; CONSCIOUS SEDATION; ENDOSCOPY, GASTROINTESTINAL; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 2342638393     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2004.01.001     Document Type: Review

References (119)

1. An Updated Report by the American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 96:2002;1004-1017
2. Daneshmend T.K., Bell G.D., Logan R.F. Sedation for upper gastrointestinal endoscopy: results of a nationwide survey. Gut. 32:1991;12-15
3. Reves J.G., Fragen R.J., Vinik R., Greenblatt D.J. Midazolam: pharmacology and uses. Anesthesiology. 62:1985;310-324
4. Kanto J.H. Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy. 5:1985;138-154
5. Dundee J.W., Halliday N.J., Harper K.W., Brogden R.N. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs. 28:1984;519-543
6. Wagner J., Wagner M.L., Hening W.A. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 32:1998;680-691
7. Hobbs W.R., Rall T.W., Verdoor T.A. Hypnotics and sedatives: ethanol. Molinoff P.B., Ruddon R.W. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th edition:1996;361-367 McGraw-Hill, New York
8. Bailey L., Ward M., Musa M.N. Clinical pharmacokinetics of benzodiazepines. J Clin Pharmacol. 34:1994;804-811
9. Dundee J.W., Lilburn J.K., Nair S.G., George K.A. Studies of drugs given before anesthesia. XXVI: lorazepam. Br J Anaesth. 46:1977;1047-1055
10. Goulenok C., Bernard B., Cadranel J.F., Thabut D., Di Martino V., Opolon P., et al. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 16:2002;361-372
11. Greenblatt D.J., Harmartz J.S., Shapiro L. Sensitivity to triazolam in the elderly. N Engl J Med. 324:1991;1691-1698
12. Sunderland T. Geriatric psychopharmacology: why does age matter? Harv Rev Psychiatry. 7:2000;311-333
13. Bell G.D. Review article: premedication and intravenous sedation for upper gastrointestinal endoscopy. Aliment Pharmacol Ther. 4:1990;103-122
14. Ghoneim M.M., Mewaldt S.P. Benzodiazepines and human memory: a review. Anesthesiology. 72:1990;926-938
15. Garcia-Morillas M., Gil-Extremera B., Caracuel-Ruiz M.D. Differential effects of hepatic cirrhosis on the plasma protein binding of drugs. Int J Clin Pharmacol Res. 4:1984;327-333
16. Hendel J. Cumulation of in the cerebrospinal fluid of the N-methyl metanaolite after long-term treatment with diazepam in man. Acta Pharmacol Toxicol. 37:1975;17-22
17. Mandelli M., Tognoni G., Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet. 3:1978;72-91
18. Herman R.J., Wilkinson G.R. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol. 42:1996;147-155
19. Iqbal M.M., Sobhan T., Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 53:2002;39-49
20. Laegreid L., Hagberg G., Lundberg A. The effect of benzodiazepines on the fetus and newborn. Neuropediatrics. 23:1992;60-67
21. Wesson D.R., Camber S., Harkey M., Smith D.E. Diazepam and desmethyldiazepam in breast milk. J Psychoactive Drugs. 17:1985;55-56
22. Patrick M.J., Tilstone W.J., Reavey P. Diazepam and breast-feeding. Lancet. 1:1972;542-543
23. Reinhart K., Dallinger-Stiller G., Dennhardt R., Heinemeyer G., Eyrich K. Comparison of midazolam, diazepam, and placebo i.m. as premedication for regional anesthesia: a randomized, double blind study. Br J Anaesth. 57:1985;294-299
24. Barker I., Butchart D.G.M., Gibson J., Lawson J.I., Mackenzie N. IV sedation for conservative dentistry: a comparison of midazolam and diazepam. Br J Anaesth. 58:1986;371-377
25. Aun C., Flynn P.J., Richards J., Major E. A comparison of midazolam and diazepam for intravenous sedation in dentistry. Anaesthesia. 39:1984;589-593
26. Arbour R.B. Propylene glycol toxicity related to high-dose lorazepam infusion: case report and discussion. Am J Crit Care. 8:1999;499-506
27. Snyder S.H., Enna E.J. The role of central glycine receptors in the pharmacologic actions of benzodiazepines. Adv Biochem Psychopharmacol. 14:1975;81-91
28. Snyder S.H., Enna E.J., Young A.B. Brain mechanisms associated with therapeutic actions of benzodiazepines: focus on neurotransmitters. Am J Psychiatr. 134:1977;662-664
29. Khanderia U., Pandit S.K. Use of midazolam hydrochloride in anesthesia. Clin Pharm. 6:1987;533-547
30. Reves J.G., Newfield P., Smith L.R. Influence of serum protein, serum albumin concentrations and dose on midazolam anaesthesia induction times. Can Anaesth Soc J. 28:1981;556-559
31. Kanto J., Aaltonen L., Himberg J.J., Hovi-Viander M. Midazolam as an intravenous induction agent in the elderly: a clinical and pharmacokinetic study. Anesth Analg. 65:1986;15-20
32. Albrecht S., Ihmsen H., Hering W., Geisslinger G., Pingemanse J., Schwilden H. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther. 65:1999;630-639
33. MacGilchrist A.J., Birnie G.G., Cook A., Scobie G., Murray T., Wathinson G. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut. 27:1986;190-195
34. Pentikainen P.J., Valisalmi L., Himberg J.J., Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 29:1989;272-277
35. Vinik H.R., Reves J.G., Greenblatt D.J., Abernethy D.R., Smith L.R. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology. 59:1983;390-394
36. Product information. Versed. 1997;Roche Laboratories, Switzerland
37. Kanto J., Sjovall S., Erkkola R., Himberg J.J., Kangas L. Placental transfer and maternal midazolam kinetics. Clin Pharmacol Ther. 33:1983;786-791
38. Crawford M.E., Carl P., Bach V., Ravlo O., Mikkelsen B.O., Werner M. A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: I. Mothers. Anesth Analg. 68:1989;229-233
39. Ravlo O., Carl P., Crawford M.E., Bach V., Mikkelsen B.O., Nielsen H.K. A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: II. Neonates. Anesth Analg. 68:1989;234-237
40. Matheson I., Lunde P.K., Bredesen J.E. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. Br J Clin Pharmacol. 30:1990;787-793
41. Skues M.A., Prys-Roberts C. The pharmacology of propofol. J Clin Anesth. 1:1989;387-400
42. Trapani G., Altomare C., Sanna E., Biggio G., Liso G. Propofol in anesthesia: mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem. 7:2000;249-271
43. Hales T.G., Lambert J.J. The actions of propofol on inhibitory amino acid receptors of bovine adrenomedullary chromaffin cells and rodent central neurons. Br J Pharmacol. 104:1991;619-628
44. Peduto V.A., Concas A., Santoro G., Biggio G., Gessa G.L. Biochemical and electrophysiologic evidence that propofol enhances GABAergic transmission in the rat brain. Anesthesiology. 75:1991;1000-1009
45. Whitehead C., Sanders L.D., Oldroyd G., Haynes T.K., Marshall R.W., Rosen M. The subjective effects of low dose propofol: a double blind study to evaluate dimensions of sedation and consciousness with low-dose propofol. Anaesthesia. 49:1994;490-496
46. Smith I., Monk T.G., White P.F., Ding Y. Propofol infusion during regional anesthesia: sedative, amnestic, and anxiolytic properties. Anesth Analg. 79:1994;313-319
47. Karski J.M., Tearsdale S.J., Boylan J., et al. Propofol for continous intravenous sedation after aortocoronary bypass graft surgery: dose finding study [abstract]. Can J Anaesth. 41:1994;A17
48. O'Connor M., Stow P., Mortimer A., Fisher A., Sear J.W. Propofol to provide sedation after coronary artery bypass surgery: a comparison of two fixed dosing regimens. Acta Anaesthesiol Belg. 43:1992;235-241
49. Polster M.R., Gray P.A., O'Sullivan G., McCarthy R.A., Park G.R. Comparison of the sedative and amnesic effects of midazolam and propofol. Br J Anaesth. 70:1993;612-616
50. Coates D.P., Monk C.R., Prys-Roberts C., Turtle M. Hemodynamic effects of infusions of the emulsion formulation of propofol during nitrous oxide anesthesia in humans. Anesth Analg. 66:1987;64-70
51. Monk C.R., Coates D.P., Prys-Roberts C., Turtle M.J., Spelina K. Haemodynamic effects of a prolonged infusion of propofol as a supplement to nitrous oxide anaesthesia. Br J Anaesth. 56:1987;954-960
52. Dundee J.W., Robinson F.P., McCollum J.S.C., Patterson C.C. Sensitivity to propofol in the elderly. Anaesthesia. 41:1986;482-485
53. Roberts F.L., Dixon J., Lewis G.T.R., Tackley R.M., Prys-Roberts C. Induction and maintenance of propofol anesthesia: a manual infusion scheme. Anaesthesia. 43:1988;14S-17S
54. 2O in humans. Anesthesiology. 68:1988;157-163
55. Wijdicks E.F. Propofol in myoclonus status epilepticus in comatose patients following cardiac resuscitation. J Neurol Neurosurg Psychiatr. 73:2002;94-95
56. Prasad A., Worrall B.B., Bertram E.H., Bleck T.P. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 42:2001;380-386
57. Begemann M., Rowan A.J., Tuhrim S. Treatment of refractory complex-partial status epilepticus with propofol: case report. Epilepsia. 41:2000;105-109
58. Cook S., Palma O. Propofol as a sole agent for prolonged infusion in intensive care. J Drug Dev. 2(Suppl 2):1989;65-67
59. Lambert A., Mitchell R., Robertson W.R. Effect of propofol, thiopentone, and etomidate on adrenal steroidogensis in vitro. Br J Anaesth. 62:1989;202-203
60. Stark S.D., Binks S.M., Dutka V.N., O'Connor K.M., Arnstein M.J., Glen J.B. A review of the safety and tolerance of propofol ("Diprivan"). Postgrad Med J. 61(Suppl 3):1985;35-37
61. McCollum J.S.C., Milligan K.R., Dundee J.W. The antiemetic action of propofol. Anaesthesia. 43:1988;239-240
62. Kanto J., Gepts E. Pharmacokinetic implications for the clinical use of propofol. Clin Pharmacokinet. 17:1989;308-326
63. Kirkpatrick T., Cockshott I.D., Douglas E.J., Nimmo W.S. Pharmacokinetics of propofol in elderly patients. Br J Anaesth. 60:1988;146-150
64. George C.F. Drug kinetics and hepatic blood flow. Clin Pharmacokinet. 4:1979;433-448
65. Servin F., Desmonts J.M., Haberer J.P., Cockshott I.D., Plummer G.F., Farinotti R. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology. 69:1988;887-891
66. Ickx B., Cockshott I.D., Barvais L., Byttebier G., De Pauw L., Vandesteene A., et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. Br J Anaesth. 81:1998;854-860
67. Gin T., Gregory M.A., Chan K., Buckley T., Oh T.E. Pharmacokinetics of propofol in women undergoing elective caesarean section. Br J Anaesth. 64:1990;148-153
68. Celleno D., Capogna G., Tomassetti M., Costantino P., Di Feo G., Nisini R. Neurobehavioural effects of propofol on the neonate following elective caesarean section. Br J Anaesth. 62:1989;649-654
69. Gin T., Yau G., Gregory M.A. Propofol during cesarean section. Anesthesiology. 73:1990;789
70. Gregory M.A., Gin T., Yau G., Leung R.K., Chan K., Oh T.E. Propofol infusion anaesthesia for caesarean section. Can J Anaesth. 37:1990;514-520
71. Olsen R.W. Barbiturates. Int Anesthesiol Clin. 26:1988;254-261
72. Olsen R.W. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem. 37(1):1981;1-13
73. Wong E.H.F., Snowman A.M., Leeb-Lundberg L.M.P., Olsen R.W. Barbiturates inhibit GABA antagonist and benzodiazepine inverse agonist binding. Eur J Pharmacol. 102:1984;205-212
74. Yang J.S.J., Olsen R.W. γ-Aminobutyric acid receptor binding in fresh mouse membranes at 22°C: ligand-induced changes in affinity. Mol Pharmacol. 32:1987;266-277
75. White P.F., Way W.L., Trevor A.J. Ketamine: its pharmacology and therapeutic uses. Anesthesiology. 56:1982;119-136
76. White P.F., Ham J., Way W.L., Trevor A.J. Pharmacology of ketamine isomers in surgical patients. Anesthesiology. 52:1980;231-239
77. Fine J., Finestone S.C. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. Anesth Analg. 52:1973;428-430
78. Bovill J.G., Dundee J.W. Alterations in response to somatic pain associated with anesthesia: ketamine. Br J Anesthesia. 43:1971;496-499
79. Erehefsky L., Saklad S.R., Jann M.W. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry. 45:1984;50-59
80. Mungas D., Magliozzi J.R., Laubly J.N., Blunden D. Effects of haloperidol on recall and information processing in verbal and spatial learning. Prog Neuropsycopharmacol Biol Psychiatry. 14:1990;181-193
81. Wilt J.L., Minnema A.M., Johnson R.F. Torsades de pointes associated with the use of intravenous haloperidol. Ann Intern Med. 119:1993;391-394
82. Jahan M.S., Farooque A.I., Wahid Z. Neuroleptic malignant syndrome. J Natl Med Assoc. 84(11):1992;966-970
83. Arnt J. Pharmacological differentiation of classical and novel antipsychotics. Int Clin Psychopharmacol. 13(Suppl 3):1998;S7-S14
84. Forsman A., Ohman R. Pharmacokinetic studies on haloperidol in man. Curr Ther Res. 20:1976;319-336
85. Forsman A., Larsson M. Metabolism of haloperidol. Curr Ther Res. 24:1978;567-568
86. Nageotte M.P., Briggs G.G., Towers C.V., Asrat T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am J Obstet Gynecol. 174:1996;1801-1805
87. Van Waes A., Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol. 9:1969;224-227
88. Stewart R.B., Karas B., Springer P.K. Haloperidol excretion in human milk. Am J Psychiatry. 137:1980;849-850
89. Yoshida K., Smith B., Craggs M., Kumar R. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychol Med. 28:1998;81
90. Merskey H., Bugduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd edition:1994;IASP Press, Seattle
91. Reisine T., Pasternal G. Opioid analgesics and antagonists. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman & Gilman's the pharmacological basis of therapeutics. 9th edition:1996;521-555 McGraw-Hill, New York
92. Jacobi J., Fraser G.L., Coursin D.B., Riker R.R., Fontaine D., Wittbrodt E.T., et al. Clinical practice guidelines for the sustained use if sedatives and analgesics in the critically ill adult. Crit Care Med. 30:2002;119-141
93. Vicari J.J. Sedation and analgesia. Gastrointest Endosc Clin N Am. 12:2002;297-311
94. Froehlich F., Schwizer W., Thorens J., Kohler M., Gonvers J.J., Fried M. Conscious sedation for gastroscopy: patient tolerance and cardiorespiratory parameters. Gastroenterology. 108:1995;697-704
95. Pereira J., Lawlor P., Vigano A., Dorgan M., Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage. 22:2001;672-687
96. McElvoy G.K. AHFS drug information 2003. 2003;2022-2061 American Society of Health-Systems Pharmacists, Bethesda
97. Bright E., Roseveare C., Dalgleish D., Kimble J., Elliott J., Shepherd H. Patient-controlled sedation for colonoscopy: a randomized trial comparing patient-controlled administration of propofol and alfentanil with physician-administered midazolam and methadone. Endoscopy. 35:2003;683-687
98. Lehmann K.A., Zech D. Morphine-6-glucuronide, a pharmacologically active morphine metabolite: a review of the literature. Eur J Pain. 12:1993;28-35
99. Anderson R., Saiers J., Abram S., Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage. 21:2001;397-406
100. Cherny N.I. Opioid analgesics: comparative features and prescribing guidelines. Drugs. 51:1996;713-737
101. Hall L.G., Oyen L.J., Murray M.J. Analgesic agents: pharmacology and application in critical care. Crit Care Clin. 17:2001;899-923
102. Flackle J.W., Flacke W.E., Bloor B.C., Van Etten A.P., Kripke B.J. Histamine release by four narcotics: a double-blind study in humans. Anesth Analg. 66:1987;723-730
103. Scholz J., Steinfath M., Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: an update. Clin Pharmacokinet. 31:1996;275-292
104. Liu L.L., Gropper M.A. Postoperative analgesia and sedation in the adult intensive care unit. Drugs. 63:2003;755-767
105. Bodeham A., Shelly M.P., Park G.R. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet. 14:1988;347-379
106. Babul N., Darke A.C., Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 10:1995;184-186
107. Umans J.G., Inturrisi C.E. Antinociceptive activity and toxicity of meperidine and normeperidine in mice. J Pharmacol Exp Ther. 223:1982;203-206
108. Holdsworth M. Opioids. Anderson P.O., Knoben J.E., Troutman W.G. Handbook of clinical drug data. 9th edition:1999;24-45 Appleton & Lange, Stamford (CT)
109. Glass P.S.A., Egan T.D. A review of the pharmacokinetics and pharmacodynamics of remifentanil. Anesth Analg. 89:1999;S7-S14
110. Burkle H., Dunbar S., Van Aken H. Remifentanil: a novel, short-acting opioid. Anesth Analg. 83:1996;646-651
111. Tegeder I., Lotsch J., Greisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet. 37:1999;17-40
112. Brenner G.M. Opioid analgesics and antagonists. Pharmacology. 2000;242-253 WB Saunders, Philadelphia
113. Jacox A., Carr D.B., Payne R., et al. Management of cancer pain: clinical practice guideline No. 9. 1994;Agency for Health Care Policy and Research, US Dept of Health and Human Services, Public Health Service, Rockville (MD)
114. Grossman S.A. Management of cancer pain: National Comprehensive Cancer Network Guidelines. Oncology. 13:1999;33-44
115. Max M.B., Payne R. Principles of analgesic use in the treatment of acute pain and cancer pain. 4th edition:1999;The American Pain Society, Glenview (IL)
116. Volles D.F., McGory R. Pharmacokinetic considerations. Crit Care Clin. 15:1999;55-75
117. Inturrisi C.E. Clinical pharmacology of opioids for pain. Clin J Pain. 18:2002;S3-S13
118. Rudner R., Jalowiecki P., Kawecki P., Gonciarz M., Mularczyk A., Petelenz M. Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl, midazolam, and propofol for outpatient colonoscopy. Gastrointest Endosc. 57:2003;657-663
119. Sa Rego M.M., Inagaki Y., White P.F. Remifentanil administration during monitored anesthesia care: are intermittent boluses an effective alternative to a continuous infusion. Anesth Analg. 88:1999;518-522